HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fekkai/Mercier partnership

This article was originally published in The Rose Sheet

Executive Summary

Laura Mercier cosmetics will be the exclusive cosmetics vendor in U.S. Frédéric Fekkai salons and spas beginning in January, in a move capitalizing on the parties' shared perspective that "true style is about enhancing one's own features and natural beauty," according to a recent release. The luxury color cosmetics brand will initially be sold at Fekkai salons in New York City, Beverly Hills, Calif. and Palm Beach, Fla., with additional locations to be added as more salons open in new markets. Frédéric Fekkai plans to open 20 retail locations in the U.S. over the next three years (1"The Rose Sheet" Oct. 2, 2006, p. 7)...

You may also be interested in...



Frédéric Fekkai Anti-Aging Hair Care Fends Off Aging “Aggressors”

Frédéric Fekkai is expanding its Fekkai Advanced Haircare collection this fall with Ageless, a line designed to combat the biological, mechanical and environmental signs of aging

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel